BioVie, Inc. Common Stock (BIVI) Stock Price

BIVIStock
$2.16+45.95%52W
Market Cap$18.25M
P/E
PEG Ratio
Div yield
Beta0.74

BIVI Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)60.87%
Price vs S&P 500 (4W)31.79%
VGM Score80.82

BIVI Earnings Surprise History

QuarterReport dateEPS estimateEPS actualSurprise
Q3 2025-$0.79-$0.98-24.05%(-$0.19)
Q2 2025-$3.60-$11.05-206.94%(-$7.45)
Q1 2025-$3.20-$1.50+53.13%(+$1.70)
Q4 2024-$4.60

BIVI Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
4.14
4.14
4.14
4.13

Industry Peers — Pharmaceuticals(570)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
BIVIBioVie, Inc. Common Stock
A$2.16
LLYEli Lilly & Co.DBC$1174.61
JNJJohnson & JohnsonDCB$268.04
ABBVABBVIE INC.DCB$255.48
MRKMerck & Co., Inc.DCB$148.35
NVSNovartis AGCCC$153.81
AZNAstraZeneca PLCCBC$162.70
NVONovo-Nordisk A/SBCC$45.61
ABTAbbott LaboratoriesCCC$112.47
PFEPfizer Inc.CDB$27.96
VRTXVertex Pharmaceuticals IncDCB$541.69

About BioVie, Inc. Common Stock

BioVie Inc. is a clinical-stage biopharmaceutical company developing therapies for neurological and liver diseases. Its lead program, NE3107, is advancing through Phase 3 clinical trials for mild to moderate Alzheimer's disease. BIV201 targets life-threatening complications of advanced liver disease, including cirrhosis from hepatitis, non-alcoholic fatty liver disease, and alcohol-related liver injury.